CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy.
Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
非毛刺状边缘和单灶性与 pCR 独立相关,并可提升模型预测 BC 对 NAC 应答的性能。
评估治疗前MRI征象与乳腺癌(BC)新辅助化疗(NAC)后病理完全缓解(pCR)的关系。
本回顾性单中心观察研究纳入2016至2020年期间接受NAC且完成乳腺MRI检查的BC患者。依据标准化BI-RADS和T2加权MRI乳腺水肿评分描述MRI检查。通过单变量和多变量逻辑回归分析评估各变量与pCR(按残余癌负荷定义)的关系。随机森林分类器采用随机划分的70%数据库进行训练,并在其余病例中验证。
129例乳腺癌中,59例(46%)NAC后达到pCR,包括管腔型7/37例(19%)、三阴性30/55例(55%)和HER2阳性22/37例(59%)。与pCR相关的临床和生物学因素包括乳腺癌亚型(p<0.001)、T分期0/I/II期(p=0.008)、Ki67较高(p=0.005)及TIL(肿瘤浸润淋巴细胞)水平较高(p=0.016)。单变量分析显示,以下MRI特征与pCR显著相关:椭圆形或圆形(p=0.047)、单灶(p=0.026)、边缘无毛刺(p=0.018)、无伴随非肿块强化(p=0.024)及MRI测量肿瘤较小(p=0.031)。多变量分析中,单灶和边缘无毛刺仍与pCR独立相关。在随机森林分类器中,将显著MRI特征加入临床生物学变量后,pCR预测敏感度(0.67比0.62)、特异度(0.69比0.67)和精确率(0.71比0.67)均显著提高。
边缘无毛刺和单灶与pCR独立相关,可提高模型预测乳腺癌对NAC应答的表现。临床相关性说明:将治疗前MRI特征与临床生物学预测因子(包括TIL)结合的多模态方法,可用于开发机器学习模型,识别治疗无应答风险患者,并考虑替代治疗策略以优化结局。要点:多变量逻辑回归显示,单灶和边缘无毛刺与pCR独立相关。乳腺水肿评分与MRI测量肿瘤大小及TIL表达相关,这不仅见于既往报道的三阴性乳腺癌,也见于管腔型乳腺癌。在机器学习分类器中加入显著MRI特征,可显著提高pCR预测敏感度、特异度和精确率。
To evaluate the association between pretreatment MRI descriptors and breast cancer (BC) pathological complete response (pCR) to neoadjuvant chemotherapy (NAC).
Patients with BC treated by NAC with a breast MRI between 2016 and 2020 were included in this retrospective observational single-center study. MR studies were described using the standardized BI-RADS and breast edema score on T2-weighted MRI. Univariable and multivariable logistic regression analyses were performed to assess variables association with pCR according to residual cancer burden. Random forest classifiers were trained to predict pCR on a random split including 70% of the database and were validated on the remaining cases.
Among 129 BC, 59 (46%) achieved pCR after NAC (luminal (n = 7/37, 19%), triple negative (n = 30/55, 55%), HER2 + (n = 22/37, 59%)). Clinical and biological items associated with pCR were BC subtype (p < 0.001), T stage 0/I/II (p = 0.008), higher Ki67 (p = 0.005), and higher tumor-infiltrating lymphocytes levels (p = 0.016). Univariate analysis showed that the following MRI features, oval or round shape (p = 0.047), unifocality (p = 0.026), non-spiculated margins (p = 0.018), no associated non-mass enhancement (p = 0.024), and a lower MRI size (p = 0.031), were significantly associated with pCR. Unifocality and non-spiculated margins remained independently associated with pCR at multivariable analysis. Adding significant MRI features to clinicobiological variables in random forest classifiers significantly increased sensitivity (0.67 versus 0.62), specificity (0.69 versus 0.67), and precision (0.71 versus 0.67) for pCR prediction.
Non-spiculated margins and unifocality are independently associated with pCR and can increase models performance to predict BC response to NAC. CLINICAL RELEVANCE STATEMENT: A multimodal approach integrating pretreatment MRI features with clinicobiological predictors, including tumor-infiltrating lymphocytes, could be employed to develop machine learning models for identifying patients at risk of non-response. This may enable consideration of alternative therapeutic strategies to optimize treatment outcomes. KEY POINTS: Unifocality and non-spiculated margins are independently associated with pCR at multivariable logistic regression analysis. Breast edema score is associated with MR tumor size and TIL expression, not only in TN BC as previously reported, but also in luminal BC. Adding significant MRI features to clinicobiological variables in machine learning classifiers significantly increased sensitivity, specificity, and precision for pCR prediction.
MEMBER ACCOUNT
登录成功会直接打开下一页。